Menlo Security Joins VMware SD-WAN Security Technology Partner Program to Deliver Secure Cloud Transformation
6.11.2019 11:00:00 EET | Business Wire | Press release
Menlo Security, a leader in cloud security, today announced a new integration with VMware SD-WAN by VeloCloud, which offers the industry’s most flexible enterprise SD-WAN architecture. The solution delivers Secure Cloud Transformation, which optimizes and secures local Internet breakouts and enables global low latency access to the Internet and business-critical SaaS applications for an enterprise’s entire local and remote workforce. The integration is available immediately to all VMware SD-WAN customers.
“Menlo Security helps some of the largest enterprises and government agencies in the world transform their infrastructure and move security to the cloud, while maintaining global visibility and control of their traffic,” said Poornima DeBolle, chief product officer at Menlo Security. “VMware SD-WAN by VeloCloud combined with the Menlo Security Cloud Platform powered by isolation redefines security and provides the industry’s most secure solution for Internet and SaaS applications.”
"VMware SD-WAN provides the optimal combination of intrinsic security in the multi-service Edge for corporate traffic as well as SD-WAN optimized access via our Network of Clouds Service gateways to the innovative Menlo Security Cloud Platform powered by isolation," said Steve Woo, senior director of product management at VMware. "Access to cloud and SaaS applications is automatically provisioned, optimized for performance and secured with VMware SD-WAN and Menlo Security Cloud Platform."
VMware SD-WAN customers have simplified their branch office networking and optimized application performance over the Internet. Secure Cloud Transformation, powered by isolation, allows companies to improve security control and visibility across their SD-WAN deployment. Moving to SD-WAN requires an enterprise to move their security to the cloud since user traffic is not backhauled to a central security stack. Menlo Security Cloud Platform allows users to go directly to the Internet while ensuring consistent and robust security controls, whether they are connecting from HQ, remote offices, on the road or in a coffee shop.
Menlo Security’s customers include some of the largest enterprises and government agencies. The company’s cloud security platform currently processes more than 500 million web requests per day. Among the company’s customers are seven of the 10 largest banks, four of the five largest credit-card issuers and some of the largest energy and transportation companies in the world.
For more information, please send an email to ask@menlosecurity.com.
Additional Resources
- Secure Cloud Transformation
- Menlo Security Secure Web Gateway
- Definitive Guide to Internet Isolation
VMware and SD-WAN by VeloCloud are registered trademarks or trademarks of VMware, Inc. in the United States and other jurisdictions.
About Menlo Security
Menlo Security protects organizations from cyber attacks by eliminating the threat of malware from the web, documents and email. Its cloud-based Isolation Secure Web Gateway scales to provide comprehensive protection across enterprises of any size, without requiring endpoint software or impacting the end user-experience. The company was named a Visionary in the Gartner Magic Quadrant for the Secure Web Gateway. Menlo Security is trusted by major global businesses, including Fortune 500 companies and financial services institutions, and backed by General Catalyst, Sutter Hill Ventures, Engineering Capital, Osage University Partners, American Express Ventures, Ericsson Ventures, HSBC and JP Morgan Chase. Menlo Security is headquartered in Palo Alto, California. For more information, visit https://www.menlosecurity.com or ask@menlosecurity.com
VMware, and VeloCloud are registered trademarks or trademarks of VMware, Inc. in the United States and other jurisdictions.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20191106005218/en/
Contact information
Lexie Janney
Merritt Group for Menlo Security
703.390.1531
janney@merrittgrp.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Galderma Receives U.S. FDA Approval for Differin ® Epiduo ® Acne Gel Prescription-to-OTC Switch22.5.2026 19:25:00 EEST | Press release
Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved Differin® Epiduo® Acne Gel (Adapalene 0.1% and Benzoyl Peroxide 2.5% Acne Treatment) for over-the-counter (OTC) use in ages 12 years and older, marking a significant Prescription-to-OTC transition in acne care. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260522074280/en/ The U.S. FDA approves Differin® Epiduo® Acne Gel Prescription-to-OTC switch This milestone represents yet another example of Galderma’s unique Integrated Dermatology strategy, demonstrating how proven innovations from its Therapeutic Dermatology portfolio can further strengthen its Dermatological Skincare offerings. The Prescription‑to‑OTC transition highlights Galderma’s scale and expertise in successfully commercializing dermatology innovations across the full spectrum of acne care. With the appro
Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia22.5.2026 17:18:00 EEST | Press release
Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for the treatment of anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia, with an orphan medicinal product designation. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260522186975/en/ Adam Plich, CEO and Co-Founder of Avanzanite Bioscience. “Thalassaemia is a complex, chronic and multisystem disease characterised by anaemia, ineffective erythropoiesis and haemo
ICE Brent and ICE WTI Perpetual Futures to Launch on OKX22.5.2026 15:30:00 EEST | Press release
OKX, a blockchain technology and trading company serving more than 120 million customers globally,and Intercontinental Exchange (NYSE: ICE), one of the world's leading providers of financial market technology and data powering global capital markets including the New York Stock Exchange, today announced plans for OKX to launch perpetual futures based on ICE's Brent Crude and WTI Crude energy benchmarks. The products are expected to be available to trade on OKX’s platform in jurisdictions where OKX is licensed to offer perpetual futures products. The new OKX contracts represent a major step forward in expanding regulated access to global commodity markets through digital asset infrastructure. This first product collaboration between OKX and ICE comes after the companies established a strategic relationship in March 2026. ICE operates some of the world’s leading exchanges, clearing houses and market data services across energy, commodities, fixed income and equities markets. ICE’s future
Enhertu ® Recommended for Approval in the EU by CHMP for Patients with Previously Treated HER2 Positive Metastatic Solid Tumors22.5.2026 15:00:00 EEST | Press release
Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the treatment of adult patients with unresectable or metastatic HER2 positive (immunohistochemistry [IHC] 3+) solid tumors who have received prior treatment and who have no satisfactory treatment options. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from patients with HER2 positive (IHC 3+) tumors in three phase 2 trials including DESTINY-PanTumor02,DESTINY-Lung01 andDESTINY-CRC02 where Enhertu demonstrated clinically meaningful responses across a broad range of tumors. The recommendation will now be reviewed by the European Commission, which has the authority
Future Health Challenge Awards USD 300,000 to Early Detection and Population Health Sensing Tools on Sidelines of World Health Assembly22.5.2026 14:45:00 EEST | Press release
Three global teams developing early detection and real-time population health monitoring solutions have secured a total of USD 300,000 on the sidelines of the 79th World Health Assembly. The winning solutions address critical challenges in early detection, continuous population insight and more timely decision making, signalling a shift in health systems from late-stage treatment to earlier intervention. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260522587414/en/ Selected from 393 submissions across 68 countries, the winning teams were recognised through the inaugural ‘Future Health Challenge 2026: Building Anticipatory Health Systems through Population Sensing’, delivered by Future Health – A Global Initiative by Abu Dhabi in collaboration with MIT Solve. Health systems globally are facing rising costs and persistent delays in diagnosis, with many conditions still identified only after symptoms become severe. At the sam
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom